cilostazol / Generic mfg. - LARVOL DELTA

Safety of Cold Snare Polypectomy in Patients on Continued Antithrombotic Therapy: A Systematic Review and Meta-Analysis (ACG 2026) - "We included randomized controlled trials (RCTs) and cohort studies assessing bleeding after CSP in AT-continuation patients (antiplatelets: aspirin, thienopyridines, cilostazol; anticoagulants: warfarin, direct oral anticoagulants; or combinations). Seven studies met inclusion criteria (3 RCTs, 4 cohorts; 1288 patients). At the patient level, immediate bleeding (intraprocedural, per study definitions) was reported in 4 of 7 studies (751 patients), pooled proportion 0.21 (95%CI, 0.12-0.34; I²=71.5%; prediction interval 0.03-0.69). Country was the only significant subgroup factor (p< 0.01)."

Retrospective data • Review • Cardiovascular • Colonic Polyps

Synergistic effects of sorafenib and cilostazol in HepG2 cells. (PubMed, J Biosci) - "In addition, combined treatment produced potent anti-angiogenic effects through suppression of VEGF and TGF-beta. These findings demonstrate a synergistic interaction between sorafenib and cilostazol and suggest that this combination may represent a promising therapeutic strategy for hepatocellular carcinoma management."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • BCL2 • CASP3 • SMAD4 • TGFB1

Suspected NIUAA after indobufen in a patient with ibuprofen allergy: a case report suggesting possible cross-reactivity. (PubMed, Front Pharmacol) - "Subsequent continued use of other concomitant medications, along with antiplatelet therapy with clopidogrel and cilostazol, did not elicit any allergic reactions; this case suggests indobufen as a possible culprit allergen, and its shared COX-1 inhibitory mechanism with ibuprofen-despite their different chemical groups-raises the possibility of cross-reactive hypersensitivity between the two agents, although this inference remains to be confirmed. Although allergic reactions to indobufen are rare in clinical practice, clinicians should remain vigilant about the potential risk of cross-reactivity when prescribing indobufen to patients with a history of NSAID hypersensitivity."

Journal • Allergy • CNS Disorders • Dermatology • Immunology • Pruritus

Efficacy and Safety of Fixed-Dose Combination Therapy with Cilostazol and Rosuvastatin in Patients with Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial. (PubMed, Cardiovasc Drugs Ther) - P3 | "In patients with symptomatic PAD, the addition of cilostazol to rosuvastatin significantly improved patient-reported health status and provided additional favorable effects on atherogenic lipid profiles beyond rosuvastatin therapy alone."

Journal • Cardiovascular • Peripheral Arterial Disease • APOB

Cilostazol Treatment for Intracerebral Hemorrhage: Targeting Dural Lymphatics. (PubMed, Stroke) - P2 | "Cilostazol treatment does not exacerbate initial bleeding or provoke hematoma expansion in the experimental ICH. These findings support clinical translation and provide mechanistic and dosing rationale for an ongoing phase II randomized trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT06504576)."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • CD31 • PECAM1

Cilostazol restores endothelial function and reduces platelet hyperactivity via PKA/ENOS/PKG and NRF2 signaling in experimental metabolic syndrome (ESC 2026) - "CZ treatment exerted hypotensive, vasodilatory, and antiplatelet effects, suggesting potential therapeutic benefit in MS through modulation of the PKA/eNOS/PKG and Nrf2/KEAP1/Catalase/GPx signaling pathways. These findings identify a mechanistic link between endothelial protection and platelet inhibition and support PDE3 inhibition as a promising strategy to counteract cardiometabolic vascular disease."

Cardiovascular • Dyslipidemia • Hypertension • CAT • NOS3

Effects of semaglutide on walking distance, symptoms and rescue treatment by baseline medical therapy and LDL cholesterol levels: insights from the STRIDE trial (ESC 2026) - "Medications were categorized by class (anti-hypertensive [AHTN], anti-thrombotic [ATT], lipid lowering [LLT], and therapies for claudication ([cilostazol or pentoxifylline, CT]). Of the 792 randomized participants, medication use at baseline was 88% AHTN, 84% LLT, 77% ATT, 35% SGLT2i, 14% CT. The proportion with LDL-C < 1.8 mmol/L (<70 mg/dL) and <1.4 mmol/L (<55 mg/dL) were 45% and 26%, respectively. The primary and secondary endpoints of change in MWD and PFWD at 52 weeks (Figure Panel A) were significantly improved with semaglutide with consistent benefit regardless of baseline medications or LDL-C."

Cardiovascular • Dyslipidemia • Peripheral Arterial Disease

Out-of-hospital cardiac arrest due to ventricular arrhythmia in patients without structural heart disease: underlying etiology and long-term outcomes from a multicenter registry (ESC 2026) - "The medications included beta-blockers in 8 patients (16%), calcium channel blockers in 9 (18%), quinidine in 5 (10%), cilostazol in 3 (6%), bepridil in 4 (8%), and amiodarone in 6 (12%); some patients received combination therapy. The high rate of appropriate ICD therapies among patients with cardiac channelopathies highlights the importance of comprehensive diagnostic evaluation. Younger patients initially diagnosed with IVF may be at increased risk of inappropriate ICD therapies due to non-lethal arrhythmias."

Clinical • Atrial Fibrillation • Cardiovascular • Heart Failure • Ventricular Tachycardia

Cilostazol and Functional Outcomes in Poor-Grade Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Analysis. (PubMed, J Clin Med) - "Cilostazol use was associated with favorable functional outcome in the primary analysis, although statistical significance was not retained in sensitivity analyses addressing missing outcomes. These findings suggest a potential therapeutic signal of cilostazol in poor-grade aneurysmal SAH, warranting prospective validation."

Clinical • Journal • Retrospective data • Cardiovascular • CNS Disorders • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

Peripheral artery disease in patients with persistent claudication after lumbar spine surgery: a primary care reassessment framework. (PubMed, Fam Med Community Health) - "Antiplatelet and statin therapy may be absent even in patients with established PAD, while symptomatic agents such as cilostazol are continued without concurrent secondary prevention...This communication provides a primary care reassessment framework integrating symptom-pattern assessment, pulse examination, ABI testing, medication reconciliation and timely vascular referral to reduce diagnostic delay and close secondary prevention gaps in patients with persistent claudication after lumbar spinal surgery. This framework represents a pragmatic clinical approach derived from existing guidelines and observational data; it has not been prospectively validated."

Journal • Review • Cardiovascular • Musculoskeletal Diseases • Orthopedics • Pain • Peripheral Arterial Disease

Isolating the ischaemic and haemorrhagic effects of factor XIa inhibitors versus classical antiplatelets in acute non-cardioembolic stroke: a component network meta-analysis (ESC 2026) - "Most milvexian doses lacked significant incremental benefit, though 25mg twice daily displayed a favourable trend despite wide intervals (iHR 0.69, 95% CI 0.35-1.37). We included 79,230 patients from 24 RCTs. Regarding ischaemic protection, the addition of classical antiplatelets provided significant incremental efficacy (cilostazol iHR 0.59, 95% CI 0.42-0.83; ticagrelor iHR 0.61, 95% CI 0.51-0.73; clopidogrel iHR 0.76, 95% CI 0.66-0.87; aspirin iHR 0.72, 95% CI 0.53-0.97). Among novel FXIa inhibitors, only asundexian 50mg demonstrated significant isolated efficacy for stroke prevention (iHR 0.74, 95% CI 0.61-0.89)."

Retrospective data • Cardiovascular • Ischemic stroke • Thrombosis

An Uninterrupted DOAC plus Single Antiplatelet Strategy for Carotid Artery Stenting in Patients with Atrial Fibrillation. (PubMed, J Neuroendovasc Ther) - "In all cases, SAPT (clopidogrel, aspirin, or prasugrel) was initiated at least 2 weeks before the procedure...One patient with elevated P2Y12 reaction units required the temporary periprocedural addition of cilostazol. No periprocedural hemorrhagic or thromboembolic complications occurred during the periprocedural period or within 3 months after CAS. Uninterrupted DAT with a DOAC and SAPT may be a feasible periprocedural management strategy for CAS in patients with NVAF, without the need for DOAC interruption or triple therapy."

Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders

Efficacy and safety of sublingual cilostazol and dexborneol for the treatment of acute ischaemic stroke: a randomised phase 2 trial in China. (PubMed, EClinicalMedicine) - "We aimed to investigate the efficacy and safety of Y-6 sublingual tablets (cilostazol and dexborneol) in ischaemic stroke patients with endovascular treatment. Large-scale phase 3 clinical trials are warranted to further this research. The National Natural Science Foundation of China; Noncommunicable Chronic Diseases-National Science and Technology Major Project; Beijing Municipal Science & Technology Commission; Capital's Funds for Health Improvement and Research; National Key R&D Program of China."

Journal • P2 data • Cardiovascular • Cerebral Hemorrhage • Ischemic stroke

Retina is a Marker for Cerebrovascular Heath (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Mayo Clinic | Trial primary completion date: Jun 2026 ➔ Jun 2030 | Trial completion date: Jun 2026 ➔ Jun 2030

Trial completion date • Trial primary completion date • CNS Disorders

Emerging Neurovascular Interventions for the Prevention of Cerebral Vasospasm and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. (PubMed, Cureus) - "Although conventional management strategies such as nimodipine administration, hemodynamic augmentation, and endovascular rescue therapy remain central to clinical practice, growing evidence suggests that delayed cerebral ischemia is a multifactorial neurovascular process extending beyond isolated large vessel vasospasm...Emerging evidence increasingly supports a broader pathophysiological model of delayed cerebral ischemia involving endothelial dysfunction, microcirculatory impairment, neuroinflammation, and autonomic dysregulation in addition to proximal arterial narrowing. Contemporary neurovascular interventions may therefore represent an important shift toward more targeted and mechanistically informed therapeutic strategies after aneurysmal subarachnoid hemorrhage, although further large-scale multicenter investigations remain necessary to establish definitive clinical benefit."

Journal • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Inflammation • Subarachnoid Hemorrhage • Vascular Neurology

Isosorbide Mononitrate/Cilostazol for Lacunar Cerebral Small Vessel Disease-Outcomes at 6 Months in the LACI-2 Randomized Controlled Trial. (PubMed, J Am Heart Assoc) - "A reduction in the composite outcome, cognitive impairment, dependency, and stroke impact was seen within 6 months of starting ISMN or cilostazol."

Journal • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Ischemic stroke • Myocardial Infarction

Effects of intravenous human albumin, enteral cilostazol, and combination therapy on the reduction of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. (PubMed, Front Neurol) - "These simulations provide planning-level projections and do not establish efficacy. The findings support continued randomized evaluation of cilostazol and albumin, with concurrent single-agent, combination, and control arms to estimate component effects and interaction effects."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Subarachnoid Hemorrhage

Cilostazol-Induced Digoxin Toxicity Presenting as Accelerated Idioventricular Rhythm and Recurrent Syncope. (PubMed, JACC Case Rep) - "AIVR in a digoxin-treated patient should prompt toxicity evaluation regardless of serum levels. The cilostazol-digoxin interaction is under-recognized and warrants proactive monitoring when these agents are coprescribed."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Peripheral Arterial Disease

Study on the Safety and Efficacy of Cilostazol Combined with Aspirin in Patients with Ischemic Stroke (ChiCTR) - P=N/A | N=458 | Recruiting | Sponsor: Drum Tower Hospital; Drum Tower Hospital

New trial • Cardiovascular • Ischemic stroke

Cilo-Asa: Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=1200 | Recruiting | Sponsor: Seoul National University Bundang Hospital

New P4 trial • Atherosclerosis • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacogenetic mechanism of cilostazol-induced headaches: Splicing-mediated loss of ABCC5 gene function. (PubMed, Br J Pharmacol) - "The rs7636910 variant reduces cilostazol-induced headaches through a signalling-based mechanism independent of drug pharmacokinetics, suggesting that transporter variants affecting endogenous substrate handling are as clinically important as drug-metabolising enzyme polymorphisms. This variant represents a candidate pharmacogenetic biomarker for identifying cilostazol-tolerant patients."

Biomarker • Journal • Pain • ABCC5

Antithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches. (PubMed, Cureus) - "This review summarizes the spectrum of cutaneous adverse reactions associated with major antithrombotic agents, including warfarin, heparins, aspirin, ticlopidine, clopidogrel, cilostazol, prasugrel, and direct oral anticoagulants (DOACs). Instead, each drug class exhibits characteristic cutaneous reaction patterns that may assist in the differential diagnosis of these reactions in clinical practice. Recognition of these drug-specific phenotypes may facilitate earlier diagnosis, improve interdisciplinary communication, and optimize the management of suspected antithrombotic drug eruptions."

Journal • Review • Cardiovascular • CNS Disorders • Dermatology • Eosinophilia • Hematological Disorders • Immunology • Steven-Johnson Syndrome • Vascular Neurology • Vasculitis

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Spaulding Rehabilitation Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular

Comparative effectiveness of dual antiplatelet therapy after revascularization in diabetes and chronic limb-threatening ischemia: a target trial emulation study. (PubMed, Cardiovasc Diabetol) - "Among patients with diabetes and CLTI undergoing lower-extremity revascularization, aspirin plus cilostazol was associated with lower risks of LEA and MACE compared with aspirin plus clopidogrel, whereas clopidogrel plus cilostazol was associated with lower MACE but not with significant limb-related benefit. These observational findings suggest that aspirin plus cilostazol may be a favorable DAPT strategy for long-term outcomes in this population; however, further prospective randomized trials are warranted to verify."

HEOR • Journal • Cardiovascular • Diabetes • Metabolic Disorders • Peripheral Arterial Disease • Type 2 Diabetes Mellitus

Cilostazol for Probable Swallow Syncope Associated With Sick Sinus Syndrome in a Nonagenarian Receiving Home-Based Care: A Case Report. (PubMed, J Gen Fam Med) - "Cilostazol 100 mg twice daily was initiated in home-based care, resulting in complete resolution of syncope over 10 months without adverse effects. Cilostazol may represent a noninvasive therapeutic option for carefully selected patients with probable swallow syncope when pacemaker implantation is not concordant with goals of care."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Congestive Heart Failure • Dementia • Heart Failure